Neuropsychiatric symptoms, APOE ε4, and the risk of incident dementia: A population-based study

Neurology

Volumn 84, Issue 9, 2015, Pages 935-943

  Pink, Anna ^a,c,d   Stokin, Gorazd B ^c   Bartley, Mairead M ^b   Roberts, Rosebud O ^b   Sochor, Ondrej ^c   Machulda, Mary M ^b   Krell Roesch, Janina ^a,c   Knopman, David S ^b   Acosta, Jazmin I ^a   Christianson, Teresa J ^b   Pankratz, V Shane ^b   Mielke, Michelle M ^b   Petersen, Ronald C ^b   Geda, Yonas E ^a,b,c  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c International Clinical Research Center   (Czech Republic)

^d PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E EPSILON 4; APOLIPOPROTEIN E4; UNCLASSIFIED DRUG;

AGED; AGITATION; ALLELE; ALZHEIMER DISEASE; APATHY; APPETITE; ARTICLE; CHARLSON COMORBIDITY INDEX; DELUSION; DEMENTIA; DEPRESSION; EUPHORIA; EXECUTIVE FUNCTION; FEMALE; GENOTYPE; HALLUCINATION; HUMAN; INCIDENCE; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MILD COGNITIVE IMPAIRMENT; MOTOR DYSFUNCTION; NEUROPSYCHIATRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; WECHSLER INTELLIGENCE SCALE; COHORT ANALYSIS; FOLLOW UP; GENETICS; HEALTH SURVEY; LONGITUDINAL STUDY; MENTAL DISORDERS; NEUROPSYCHOLOGICAL TEST; PROCEDURES; PSYCHOLOGY; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; APOLIPOPROTEIN E4; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84924119736     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001307     Document Type: Article

References (40)

1. Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013;9:208-245.
2. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-1342.
3. Petersen RC. Clinical practice: mild cognitive impairment. N Engl J Med 2011;364:2227-2234.
4. Teng E, Lu PH, Cummings JL. Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease. Dement Geriatr Cogn Disord 2007;24:253-259.
5. Robert PH, Berr C, Volteau M, et al. Importance of lack of interest in patients with mild cognitive impairment. Am J Geriatr Psychiatry 2008;16:770-776.
6. Ramakers IH, Visser PJ, Aalten P, Kester A, Jolles J, Verhey FR. Affective symptoms as predictors of Alzheimer's disease in subjects with mild cognitive impairment: a 10-year follow-up study. Psychol Med 2010;40:1193-1201.
7. Palmer K, Berger AK, Monastero R, Winblad B, Backman L, Fratiglioni L. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology 2007;68:1596-1602.
8. Brodaty H, Heffernan M, Draper B, et al. Neuropsychiatric symptoms in older people with and without cognitive impairment. J Alzheimers Dis 2012;31:411-420.
9. Ramachandran G, Marder K, Tang M, et al. A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease. Neurology 1996;47:256-259.
10. Scarmeas N, Brandt J, Albert M, et al. Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease. Neurology 2002;58:1182-1188.
11. Geda YE, Knopman DS, Mrazek DA, et al. Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch Neurol 2006;63:435-440.
12. Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008;30:58-69.
13. St Sauver JL, Grossardt BR, Yawn BP, Melton LJ III, Rocca WA. Use of a medical records-linkage system to enumerate a dynamic population over time: the Rochester Epidemiology Project. Am J Epidemiol 2011;173:1059-1068.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.
15. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
16. Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC. The Short Test of Mental Status: correlations with standardized psychometric testing. Arch Neurol 1991;48:725-728.
17. Rey A. L'examen clinique en psychologie. Paris: Presses Universitaires de France; 1964.
18. Wechsler D. Wechsler Memory Scale-Revised. New York: The Psychological Corporation; 1987.
19. Kaplan E, Goodglass H, Brand S. Boston Naming Test. Philadelphia: Lea & Febiger; 1983.
20. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corporation; 1981.
21. Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271-276.
22. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194.
23. Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000;12:233-239.
24. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210-216.
25. Geda YE, Roberts RO, Mielke MM, et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study. Am J Psychiatry 2014;171:572-581.
26. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
27. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.
28. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
29. Fleisher AS, Chen K, Liu X, et al. Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging 2013;34:1-12.
30. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752-758.
31. Szklo M, Nieto FJ. Epidemiology: Beyond the Basics. Gaithersburg: Aspen; 2000.
32. Selkoe DJ. Preventing Alzheimer's disease. Science 2012;337:1488-1492.
33. Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry 2013;21:685-695.
34. Chan WC, Lam LC, Tam CW, et al. Neuropsychiatric symptoms are associated with increased risks of progression to dementia: a 2-year prospective study of 321 Chinese older persons with mild cognitive impairment. Age Ageing 2011;40:30-35.
35. Geda YE, Schneider LS, Gitlin LN, et al. Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement 2013;9:602-608.
36. Kokmen E, Ozsarfati Y, Beard CM, O'Brien PC, Rocca WA. Impact of referral bias on clinical and epidemiological studies of Alzheimer's disease. J Clin Epidemiol 1996;49:79-83.
37. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010;75:494-499.
38. Lopez OL, Becker JT, Chang YF, et al. Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Study-Cognition Study. Neurology 2012;79:1599-1606.
39. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-46.
40. Patel CJ, Ioannidis JPA. Placing epidemiological results in the context of multiplicity and typical correlations of exposures. J Epidemiol Community Health 2014;68:1096-1100.